A polymer-(tandem drugs) conjugate for enhanced cancer treatment.

Abstract

A novel strategy for combination chemotherapy (platinum and demethylcantharidin) via a polymer-(tandem drugs) conjugate for enhanced cancer treatment is demonstrated. Cisplatin can be released inside cell by reduction to attack DNA, while DMC will be hydrolyzed subsequently to block DNA-damage-induced defense mechanisms by serine/threonine phosphatase PP2A inhibition. Synergistic effect of the polymer-(tandem drugs) conjugate causes complete suppression of H22 liver tumor xenografts without recurrence.

• Authors: Dongfang Zhou, Haihua Xiao, Fanbo Meng, Xiaoyuan Li, Yuxin Li, Xiabin Jing, Yubin Huang
• Journal: Advanced healthcare materials (Adv Healthc Mater) Vol. 2 Issue 6 Pg. 822-7 (Jun 2013) ISSN: 2192-2640 [Print] Germany
• PMID: 23296686 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Chemical References

• Nanocapsules
• Polymers
• demethylcantharidin
• Platinum
• Cantharidin

Topics

• Animals
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, chemistry)
• Cantharidin (administration & dosage, analogs & derivatives, chemistry)
• Cell Line, Tumor
• Liver Neoplasms (drug therapy, pathology)
• Mice
• Nanocapsules (administration & dosage, chemistry)
• Platinum (administration & dosage, chemistry)
• Polymers (chemistry)
• Treatment Outcome